Publications by authors named "R I Grove"
Article Synopsis
- Cabotegravir plus rilpivirine (CAB + RPV) is an effective long-acting injectable treatment for maintaining HIV-1 virologic suppression, and this analysis looked at its effects based on participants' body mass index (BMI).
- Data was collected from various trials over periods ranging from 48 to 152 weeks, focusing on virologic outcomes, confirmed failures, and safety across different BMI categories.
- Results showed similar efficacy and tolerability for CAB + RPV LA in both lower and higher BMI groups, with high rates of HIV-1 RNA suppression and comparable safety profiles.
Examining sub-threshold autistic traits in non-autistic first-degree relatives of individuals on the autism spectrum, known as the Broad Autism Phenotype (BAP), could provide new insights into the associations and familial aggregation of autistic traits. This study was a retrospective cross-sectional study of parents (n = 1008), probands with autism (n = 613), and unaffected siblings (n = 221) of probands with autism. BAP traits were examined by the BAP Questionnaire and Communication Checklist-Adult in parents, Autism Developmental Observation Scale-Second edition in probands, and Social Responsiveness Scale in siblings.
View Article and Find Full Text PDFBackground: Drug resistance testing aids in appropriate antiretroviral therapy selection to improve treatment success but may not be readily available. We evaluated the impact of switching to dolutegravir/lamivudine (DTG/3TC) using pooled data from the TANGO and SALSA trials in adults who were virologically suppressed with or without historical resistance results at screening.
Methods: Adults who were virologically suppressed (HIV-1 RNA <50 copies/mL for >6 months) with no prior virologic failure were randomized to switch to DTG/3TC (TANGO, n = 369; SALSA, n = 246) or continue their current antiretroviral regimen (CAR; TANGO, n = 372; SALSA, n = 247).
Article Synopsis
- - The study examines the safety and outcomes of a long-acting HIV treatment regimen, Cabotegravir (CAB) + Rilpivirine (RPV), focusing on injection site reactions (ISRs) experienced by participants across several trials.
- - Analysis of injection techniques from healthcare providers revealed that practices such as slow injection speed and bringing the medication to room temperature helped minimize discomfort for patients during the injection process.
- - Overall, the injections showed good tolerability, with most ISRs being mild to moderate and lasting only a few days, indicating that the CAB + RPV regimen is a viable option for long-term HIV maintenance therapy.
Objectives: Women represent >50% of people with HIV globally but have historically been underrepresented in clinical trials. We evaluated the efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) vs continuing their current antiretroviral regimen (CAR) by sex assigned at birth (female and male) in virologically suppressed adults with HIV-1 without prior virological failure in a pooled analysis of two randomized controlled trials.
Methods: This analysis included 48-week data from the phase 3 TANGO and SALSA studies.